Oligonucleotide & Peptide Therapeutics
-低聚核苷酸与胜肽疗法波士顿年会-
日期:2018年3月26-28日
地点:美国马萨诸塞州剑桥,Boston Marriott Cambridge

已知的疾病标的中能够成功满足治疗需求的寥寥无几。我们对疾病生物学的了解持续超过我们发展治疗药物的能力,找出一个新方法尽可能破解这个「无法药物化」的标的群体之需求已经迫在眉梢。低聚核苷酸与胜肽疗法作为面对此挑战的新兴关键模式,不但可以生产高度专一性、多样性的安全药物,更比传统小分子药物及生物制剂能够对应更广泛的标的。

在美国麻州由Cambridge Healthtech Institute (CHI)所主办的第3届Oligonucleotide and Peptide Therapeutics (OPT) Boston已在业界建立巩固地位,将聚集致力于低聚核苷酸与胜肽疗法开发的主要企业与技术供应商代表,针对次世代药物的发现、开发、运输等各领域的进步进行讨论。本活动将为期三天,网罗了创药、运输、早期阶段临床研究等主题的两大主题研讨会之外,另将举行聚焦于罕见疾病治疗应用的主题论坛。

 
 

 
 

2017 Features

200+ Participants • 84% from Leading Biotech & Pharma Companies • 43% growth in 2017

"No events go without a hitch, but your crack team met all the obstacle[s] head on, to our complete satisfaction. We've already signed up for the next event."
- Rick N., President, Oligo Factory

"It was my first time attending the show, and I was very impressed with the variety of speakers and content."
- Chris M., Ph.D. , Director, Business Development, Bachem Americas, Inc.

"This three-day meeting combines frontier works from both academic and industry which truly illustrated the current status of oligonucleotides therapeutics."
- Patrick L., Ph.D., President & CEO, Sirnaomics, Inc.